Abstract 4401
Background
In Feb 2015, palbociclib plus letrozole (P+L) became the first cyclin-dependent-kinase 4/6 inhibitor approved for mBC/aBC in the US. Until now, long-term outcomes studies have included a limited number of patients receiving P+L. The objective of this study is to describe real-world patient characteristics and clinical effectiveness associated with P+L as initial endocrine-based therapy use 4 years post approval.
Methods
Adult postmenopausal women diagnosed with metastatic HR+/HER2- breast cancer who initiated P+L as first-line therapy on or after 2/3/2015 were identified by providers in the Cardinal Health Oncology Provider Extended Network, including 1800 oncologists/hematologists in the US. A subset of providers abstracted data related to patient characteristics and clinical outcomes including disease response and disease progression into an electronic case report from (eCRF). Data were abstracted from the time of initiation of P+L through Feb 2019 (or end of follow up/death). Providers were shown response classification schema corresponding to RECIST v1.1 and asked to indicate the patient’s best response if recorded. The objective response rates (ORR – incl. complete response [CR] and partial response [PR]), clinical benefit rates (CBR – incl. CR+PR+stable disease [SD] >24 wks), and progression-free survival (PFS) rate at 12-month were reported. Each eCRF was reviewed by independent clinical staff; source data was verified on 10% of the patients.
Results
31 providers submitted 202 eCRFs, of which, 193 were eligible. Median follow-up from 1L P+L initiation was 15.4 months, 45.6% of patients had discontinued P+L at data cut-off. Table shows key patient characteristics and ORR, CBR, and PFS rate at 12-month, each showing benefit of 1L P+L in the real-world.Table:
338P
N = 193 | All |
---|---|
Mean age at diagnosis, yrs | 62.7 |
Non-Hispanic white, % | 74.6 |
Black/African-American, % | 17.1 |
ECOG-PS 0/1, % | 89.6 |
N0, % | 22.8 |
Visceral mets, % | 51.3 |
Bone only mets, % | 25.4 |
ORR, % | 65.8 |
CR | 9.8 |
PR | 56.0 |
CBR†, % | 88.0 |
CR | 12.7 |
PR | 61.3 |
SD† | 14.0 |
12-month PFS, % | 74.5 |
†Excluding 43 patients with duration of treatment <24 wks
Conclusions
These real-world data demonstrate the benefit of 1L P+L 4 years post approval in the US and support the clinical benefit of 1L P+L reported in randomized clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Pfizer Inc.
Funding
Pfizer Inc.
Disclosure
J. Kish: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. J. Trocio: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. T. Miller: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. D. Nero: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. D. Liassou: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc. X. Liu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. L. McRoy: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer Inc. B. Feinberg: Full / Part-time employment: Cardinal Health; Advisory / Consultancy, Paid consultant in connection with the development of this abstract: Pfizer Inc.
Resources from the same session
1309 - Quantifying the Effects of the Korean National Cancer Screening Program on Cervical Cancer Mortality
Presenter: Nhung Bui
Session: Poster Display session 2
Resources:
Abstract
1346 - Spread of tumor and adverse events after modified radical hysterectomy for FIGO Stage IB1 cervical cancer patients with tumor diameter preoperatively estimated 2 cm or less: Japan Clinical Oncology Group trial (JCOG1101); exploratory analysis before primary analysis.
Presenter: Takahide Arimoto
Session: Poster Display session 2
Resources:
Abstract
5352 - Impact of Combined Interstitial and Intracavitary Brachytherapy in locally advanced Cervical cancer: A Survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster Display session 2
Resources:
Abstract
2049 - Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer
Presenter: Chel Hun Choi
Session: Poster Display session 2
Resources:
Abstract
1923 - Disparities starting adjuvant chemotherapy for locally advanced cervix cancer in the international, academic, randomised, phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)
Presenter: Linda Mileshkin
Session: Poster Display session 2
Resources:
Abstract
3284 - Primary results from CECILIA, a global single-arm phase 2 study evaluating bevacizumab (BEV), carboplatin (C) and paclitaxel (P) for advanced cervical cancer (aCC)
Presenter: Andres Redondo
Session: Poster Display session 2
Resources:
Abstract
843 - Prognostic and clinicopathological significance of PD-L1 in patients with cervical cancer: a meta-analysis
Presenter: Xiaobin Gu
Session: Poster Display session 2
Resources:
Abstract
1020 - Clinical impact of molecular profiling of cervical cancer (CC) patients (pts) in a dedicated Phase I (P1) unit
Presenter: Mariana Scaranti
Session: Poster Display session 2
Resources:
Abstract
872 - Comparative proteomic profiles of cervical cancer and paried paracancerous tissue and the potential effects of DUSP7 over-expression through inhibiting RAS pathway on the biological characteristics of human cervical cancer cell line SIHA
Presenter: Xuan Jiang
Session: Poster Display session 2
Resources:
Abstract
1988 - Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix
Presenter: Semir Vranic
Session: Poster Display session 2
Resources:
Abstract